KONGRESSBERICHTE, VIDEOS & SLIDES
We invite you to take part in the 4th Zürich Immuno-Oncology Symposium recorded by ONCOLETTER & organized by the Comprehensive Cancer Center Zürich where a panel of renowned national and international experts will provide you with an overview of the field.
Oncoletter is providing you with the most important news from the conference and with useful links to more information on the conference website such as abstracts and session links.
The EHA Annual Congress is a forum for original unpublished data, for sharing ideas about haematological innovation, as well as for disseminating evidence-based knowledge of primary clinical relevance.
Oncoletter - like a quick guide - provides you with a choice of some of the important clinical studies (with links leading to the EHA abstracts) presented at the 24th EHA in Amsterdam.
Cancer experts - more than 33'100 professionals - from around the world are gathering to share the latest clinical cancer research - > 2400 accepted abstracts - impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in targeted therapies for pancreatic, prostate, and pediatric cancers, as well as new approaches to overcoming limited access to cancer care, are among the topics that will be highlighted. The theme of this year’s conference is caring for Every Patient, learning from every Patient.
Senologie Update 2019 - Risikoreduzierende Mastektomie, Deeskalation Chemo- und Radiotherapie, Familienplanung und Antikonzeption - Lake Side Zürich
Wir möchten Sie herzlich zu den Webcasts vom Senologie-Update am 9. Mai 2019 im Lake Side Zürich einladen.
On behalf of VJONCOLOGY Oncoletter attended the ELCC 2019 and interviewed several experts in the field of lung cancer.
Aktuelle Empfehlungen der Kommission Mamma der AGO 2019 15./.16. März 2019
Precision oncology reveals new opportunities for patients with malignant diseases. This is based on the rapid developments of diagnostic tools, which allow to identifying oncogenic alterations in common as well as in rare malignancies and may provide patients access to targeted treatment options.
The Comprehensive Cancer Center Zürich offers a wide range of platforms for molecular analysis of tumors and liquid biopsies and has established a molecular tumor board, which meets weekly to interpret molecular results and make recommendations for therapy.
At the first Zürich Precision-Oncology Symposium, a panel of national and international experts will provide an overview and discuss recent developments of the field.
Oncoletter reports on the symposium with links and short conclusions from abstracts and lectures as well as statements by experts.